Denosumab-Associated Hypocalcemia Risk

Mechanism and Risk Profile

Denosumab, a RANKL inhibitor, directly suppresses bone resorption, increasing hypocalcemia risk, particularly in patients who depend on bone turnover to maintain calcium homeostasis, according to the Journal of Clinical Oncology 1
The risk of denosumab-induced hypocalcemia is elevated compared to zoledronic acid, with denosumab showing higher hypocalcemia rates in head-to-head comparisons, as reported by the American Academy of Orthopaedic Surgeons 2

Patients with impaired renal function (creatinine clearance <30 mL/min or dialysis patients) require close monitoring due to increased risk of hypocalcemia, as stated by the Journal of Clinical Oncology 1

Before initiating denosumab, it is essential to verify and correct ionized calcium levels, PTH levels, magnesium levels, and vitamin D status, and assess renal function, as recommended by the Journal of Clinical Oncology 1 and Praxis Medical Insights 3, 4
Patients should receive daily calcium and vitamin D3 supplementation, as recommended by the American Academy of Orthopaedic Surgeons 2
Magnesium deficiency must be corrected before administering calcium, as calcium supplementation will be ineffective without adequate magnesium, as noted by Praxis Medical Insights 4